EcoDrugPlus

Platelet Derived Growth Factor Subunit B

Ensembl ID : ENSCHYG00000014910
Gene Symbol: PDGFB
1 Cross references
263 Possible Orthologues:

Polo Like Kinase 1

Ensembl ID : ENSCHYG00000001616
Gene Symbol: PLK1
1 Cross references
188 Possible Orthologues:

Polo Like Kinase 4

Ensembl ID : ENSCHYG00000002235
Gene Symbol: PLK4
1 Cross references
215 Possible Orthologues:

Poly(Adp-Ribose) Polymerase 1

Ensembl ID : ENSCHYG00000009348
Gene Symbol: PARP1
1 Cross references
206 Possible Orthologues:

Poly(Adp-Ribose) Polymerase 2

Ensembl ID : ENSCHYG00000016011
Gene Symbol: PARP2
1 Cross references
186 Possible Orthologues:

Poly(Adp-Ribose) Polymerase Family Member 3

Ensembl ID : ENSCHYG00000013999
Gene Symbol: PARP3
1 Cross references
200 Possible Orthologues:

Porcupine O-Acyltransferase

Ensembl ID : ENSCHYG00000012176
Gene Symbol: PORCN
1 Cross references
266 Possible Orthologues:

Potassium Calcium-Activated Channel Subfamily M Alpha 1

Ensembl ID : ENSCHYG00000006117
Gene Symbol: KCNMA1
1 Cross references
297 Possible Orthologues:

Potassium Calcium-Activated Channel Subfamily N Member 4

Ensembl ID : ENSCHYG00000001881
Gene Symbol: KCNN4
1 Cross references
191 Possible Orthologues:

Potassium Inwardly Rectifying Channel Subfamily J Member 11

Ensembl ID : ENSCHYG00000014523
Gene Symbol: KCNJ11
1 Cross references
190 Possible Orthologues:

Potassium Inwardly Rectifying Channel Subfamily J Member 2

Ensembl ID : ENSCHYG00000004266
Gene Symbol: KCNJ2
1 Cross references
273 Possible Orthologues:

Potassium Inwardly Rectifying Channel Subfamily J Member 3

Ensembl ID : ENSCHYG00000022137
Gene Symbol: KCNJ3
1 Cross references
229 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).